JAK inhibitors plus standard of care vs placebo or usual careAll‐cause mortality (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection1 finding from 1 reviewJanus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes onlyno estimate extracted6 studies · 11145 participantsModerate
JAK inhibitors plus standard of care vs placebo or usual careAll‐cause mortality (up to day 60) · hospitalised people with confirmed SARS‐CoV‐2 infection1 finding from 1 reviewJanus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 1626 participantsHigh